Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Jefferies Downgrades NGM Biopharmaceuticals to Hold

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.
byBenzinga Newsdesk
October 17, 2022
1 minute read
Total
0
Shares
0
0
0
0
0
0

Jefferies analyst Dennis Ding downgrades NGM Biopharmaceuticals (NASDAQ:NGM) from Buy to Hold.

 
Total
0
Shares
Share 0
Tweet 0
Share 0
Share 0
Share 0
Share 0